"Veel mensen zijn door een ziekte afhankelijk van medicijnen. Goede medicijnen maken hun leven beter. Hiervoor is veel onderzoek nodig. Dat doen we bij ICON, samen met gezonde deelnemers. Wereldwijd is ICON de grootste onafhankelijke onderzoeker van geneesmiddelen. In Nederland werken ruim 1.000 mensen, zoals artsen, onderzoekers en verpleegkundigen, die elk nieuw middel uitgebreid testen. Aan de onderzoeken doen een heleboel gezonde deelnemers mee, en soms ook patiënten. Pas na veelvuldig onderzoek met goede resultaten mag een nieuw middel worden voorgeschreven. Deelnemers aan geneesmiddelenonderzoek zijn dus ontzettend belangrijk om patiënten zo snel mogelijk te kunnen helpen met een nieuw of beter medicijn."

During the past decade, PRA Health Sciences (PRA) - Early Development Services (EDS) conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 1 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 1 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "PRA Health Sciences (PRA) - Early Development Services (EDS)" #1 sponsor was "Pfizer" with 2 trials, followed by "Bial - Portela C S.A." with 1 trials sponsored, "CrystalGenomics, Inc." with 1 trials sponsored, "Medicines for Malaria Venture" with 1 trials sponsored and "Michael Hoelscher" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "PRA Health Sciences (PRA) - Early Development Services (EDS)" #1 collaborator was "Leibniz Institute for Natural Product Research and Infection Biology Hans Knöll Institut" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "PRA Health Sciences (PRA) - Early Development Services (EDS)" are "Fungal Infection" (2 trials), "Bacterial Infections Respiratory" (1 trials), "Healthy" (1 trials), "Lung Diseases" (1 trials) and "Malaria" (1 trials). Many other conditions were trialed in "PRA Health Sciences (PRA) - Early Development Services (EDS)" in a lesser frequency.

Most popular intervention types in "PRA Health Sciences (PRA) - Early Development Services (EDS)" are "Drug" (6 trials). Other intervention types were less common.

The name of intervention was led by "400 mg BIA 5-1058" (1 trials), "500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043" (1 trials), "APX001" (1 trials), "APX001 multiple oral doses 1" (1 trials) and "APX001 multiple oral doses 2" (1 trials). Other intervention names were less common.

The vast majority of trials in "PRA Health Sciences (PRA) - Early Development Services (EDS)" are 4 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "PRA Health Sciences (PRA) - Early Development Services (EDS)". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in PRA Health Sciences (PRA) - Early Development Services (EDS), undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in PRA Health Sciences (PRA) - Early Development Services (EDS), 6 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

PRA Health Sciences (PRA) - Early Development Services (EDS) has several departments that took part in Clinical trials: "PRA-EDS" - 6 trials